In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forest,Paion end stroke collaboration

Executive Summary

Forest Laboratories and Paion GMBH (developing drugs for stroke and other thrombotic diseases) will jointly develop and market, in the US and Canada, Paion's ischemic stroke candidate desmoteplase, a Phase II plasminogen activator (a blood clot-dissolving agent) that was recently granted fast-track status for an expedited FDA review.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies